Cargando…

Metabolic syndrome status over 2 years predicts incident chronic kidney disease in mid-life adults: a 10-year prospective cohort study

We investigated whether changes in MetS status over two years modify the 10-year risk of CKD and proteinuria. A prospective cohort study was conducted in 7,251 subjects without CKD at baseline. We categorized subjects according to MetS status over two years: non-MetS (no MetS at either visit), inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, So Jin, Lee, Hun Ju, Oh, Hyun jeong, Go, Taehwa, Kang, Dae Ryong, Kim, Jang Young, Huh, Ji Hye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095861/
https://www.ncbi.nlm.nih.gov/pubmed/30115983
http://dx.doi.org/10.1038/s41598-018-29958-7
Descripción
Sumario:We investigated whether changes in MetS status over two years modify the 10-year risk of CKD and proteinuria. A prospective cohort study was conducted in 7,251 subjects without CKD at baseline. We categorized subjects according to MetS status over two years: non-MetS (no MetS at either visit), intermittent MetS (positive for MetS at one assessment), and persistent MetS (positive for MetS at two assessments). The hazard ratio (HR) of new-onset CKD over 10-year was calculated using Cox models. During the 10-year follow-up period, 923 (12.7%) developed CKD. Compared to the non-MetS group, the fully adjusted HR for new-onset CKD was the highest in the persistent MetS group (HR, 1.53; 95% CI, 1.23–1.90), followed by the intermittent MetS group (HR, 1.29; 95% CI, 1.04–1.59) (P for trend <0.001). The HR for developing proteinuria was 1.79 (95% CI, 1.15–2.79) in the persistent MetS group and 0.70 (95% CI, 0.42–1.19) in the intermittent MetS group when the non-MetS group was considered as the reference group. Temporal changes in MetS status over two years influenced the 10-year risk of incident CKD and proteinuria. Our findings suggest that monitoring and strictly controlling MetS are important in preventing renal function decline.